Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05029063
PHASE3

Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters

Sponsor: Ottawa Hospital Research Institute

View on ClinicalTrials.gov

Summary

The purpose of the full trial is to determine the efficacy and safety of prophylactic dose rivaroxaban to prevent VTE among cancer patients with CVC.

Official title: Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters: a Randomized Controlled Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

1828

Start Date

2022-10-05

Completion Date

2027-12

Last Updated

2025-07-09

Healthy Volunteers

No

Interventions

DRUG

Rivaroxaban 10 MG

Identical comparator drug

Locations (11)

Nova Scotia Health

Halifax, Nova Scotia, Canada

William Osler Health System

Brampton, Ontario, Canada

HHS - Juravinski Hospital

Hamilton, Ontario, Canada

Ottawa Hospital Research Institute- The Ottawa Hospital

Ottawa, Ontario, Canada

Sault Area Hospital

Sault Ste. Marie, Ontario, Canada

Niagara Health

St. Catharines, Ontario, Canada

Windsor Regional Hospital

Windsor, Ontario, Canada

CISSS Montérégie-Centre HOPITAL CHARLES LEMOYNE

Greenfield Park, Quebec, Canada

Centre Intégré de santé et de services sociaux de Chaudière-Appalaches

Lévis, Quebec, Canada

Jewish General Hospital

Montreal, Quebec, Canada

McGill University Health Center

Montreal, Quebec, Canada